Dengue Vaccines Market: Getting Back To Growth | GlaxoSmithKline, Pfizer, Sanofi Pasteur

A new business intelligence report released by AMA Research with title "Dengue Vaccines Market Insights, Forecast to 2026" provides latest updates and strategic steps taken by competition along with growth estimates of market size. The Dengue Vaccines Market report gives clear visions how the research and estimates are derived through primary and secondary sources considering expert opinion, patent analysis, latest market development activity and other influencing factors.

Some of the key players profiled in the study are
Sanofi Pasteur Inc (France), Merck & Co Inc (United States), GlaxoSmithKline (United Kingdom ), Pfizer (United States), Instituto Butantan (Brazil), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Limited (India), GeneOne Life Science Inc (South Korea), Medigen Vaccine Biologics Corporation (China), Merck Sharp & Dohme (United States)

Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/769-global-dengue-vaccines-market

Market Overview of Dengue Vaccines
Dengue is a viral disease transmitted by infected mosquitoes, particularly female mosquito of Aedes aegypti responsible vector to transmit the virus that causes dengue. Dengue causes sudden fever and pain in the joints. While vaccines are preventive measures taken to cure any disease by facilitating immunity to develop protection from disease. It is a biological preparation that provides active acquired immunity, vaccines are consisting of substance-related to disease-causing microorganism and are sometimes made from weak or killed forms of the microbe, its toxins, or its proteins. Dengue vaccine is mainly CYD tetravalent dengue vaccine from Sanofi Pasteur (France)is leading for dengue vaccines. A live attenuated vaccine known as Dengvaxia, developed by Sanofi, launched and approved license in 2015. Dengvaxia is a mixture of four monovalent chimeric vaccine viruses, CYD-1, CYD-2, CYD-3, and CYD-4, produced using Vero cells. These four CYDs are based on the yellow fever virus (YFV) 17D vaccine vector backbone. First licenses approved in Mexico in 2015 for 9-45 individuals for 20 countries.

Market Trends
• Two New Live Attenuated Dengue Vaccines Are Currently In Phase Iii Efficacy Trials
• Dsv4 Process Development And Scale-Up Work Are Currently In Progress

Drivers
• Growing Demand due to Rising in Infection Level

Challenges
• Dengue Vaccines Are Challenged By Critical Issues Like Lack Of Animal Models For The Disease And Absence Of Suitable Markers Of Protective Immunity
• New Advances In Dengue Pathogenesis And Immune Response Will Shed Light On The Approach Needed To Make An

Opportunities
• Highly Demanded In Rainy Season

If you are involved in the Dengue Vaccines industry or aim to be, then this study will provide you inclusive point of view. It’s vital you keep your market knowledge up to date segmented by major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

Regulatory Factors
On 1st May 2019, the FDA approves the first vaccine for dengue fever, but with major restrictions. The Food and Drug Administration approved the first vaccine against dengue fever, one that protects against a common disease but has generated significant controversy due to evidence it can increase the risk of severe infection in some people. Dengvaxia was licensed in 2015. But it caused a major scandal two years ago in the Philippines. After nearly a million Filipino children had been vaccinated with Dengvaxia, the drug's manufacturer, Sanofi, announced that the inoculation might make dengue worse in some people.

Market Insights
On January 28, 2020, The FDA has accepted for Priority Review the supplemental Sanofi’s Biologics License Application (sBLA) for Dupixent (dupilumab) as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The target action date for the FDA decision is May 26, 2020. Dupixent would be the first biologic medicine available in the U.S. for these children

Merger Acquisition
In January 2020 Sanofi Completes Acquisition of Synthorx, Inc. Synthorx, Inc. is now a fully owned subsidiary of Sanofi. Sanofi announced the successful completion of its acquisition of Synthorx, Inc. (Synthorx) for USD 68 per share in cash.

For Early Buyers | Get Up to 10-25% Discount on Premium Version of this Report: https://www.advancemarketanalytics.com/request-discount/769-global-dengue-vaccines-market

The Dengue Vaccines Market segments and Market Data Break Down are illuminated below:
by Application (Prevention of dengue, Enhanced the immunity), End Users (Government organizations, Medical clinics, Non-profit Organization, Diagnostic centers), Vaccines (Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Nucleic Acid-Based Vaccines)

Furthermore, the years considered for the study are as follows:
Historical year – 2015-2020
Base year – 2020
Forecast period** – 2021 to 2026 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Region Included are: North America, Europe, Asia Pacific, Oceania, South America, Middle East & Africa

Country Level Break-Up: United States, Canada, Mexico, Brazil, Argentina, Colombia, Chile, South Africa, Nigeria, Tunisia, Morocco, Germany, United Kingdom (UK), the Netherlands, Spain, Italy, Belgium, Austria, Turkey, Russia, France, Poland, Israel, United Arab Emirates, Qatar, Saudi Arabia, China, Japan, Taiwan, South Korea, Singapore, India, Australia and New Zealand etc.

Get More Information & Customization: https://www.advancemarketanalytics.com/enquiry-before-buy/769-global-dengue-vaccines-market

Important Features that are under offering & key highlights of the report:
- Market Data Segmentation with production, consumption, revenue (million USD), and Price Analysis
- Detailed overview of Dengue Vaccines market
- Changing market dynamics of the industry and Impact of Influencing Factors
- In-depth market segmentation by Type, Application and other major segments etc.
- To analyse and forecast the Dengue Vaccines market, in terms of value and volume.
- Which segment has the potential to gain the highest market share?
- To help decision maker from new offer perspective and benchmark existing marketing strategy.
- Correlate cost structure historical data with key business segments.
- Analyse marketing contribution and customer acquisition by up-selling and cross selling.
- Identifying Influencing factors keeping Dengue Vaccines Market Intense, factored with periodic analysis of CR4 & CR8 concentration ratio & HHI Index.

Major Highlights of TOC:
Chapter One: Market Overview
1.1. Introduction
1.2. Scope/Objective of the Study

Chapter Two: Executive Summary
2.1. Introduction

Chapter Three: Market Dynamics
3.1. Introduction
3.2. Market Drivers, Trends, Challenges, Opportunities

Chapter Four: Market Factor Analysis
4.1. Porters Five Forces
4.2. Supply/Value Chain
4.3. PESTEL analysis
4.4. Market Entropy
…………
Chapter Nine: Methodology and Data Source

Key questions answered
• Influential trends or factors that is booming demand and restraints in the market.
• What is the market concentration? Is it fragmented or highly concentrated?
• Dengue Vaccines Market Trends (Drivers, Constraints, Opportunities, Threats, Investment Opportunities, and Strategic Recommendations)
• Market share analysis of the top industry players…

Read Detailed Index of full Research Study at @ https://www.advancemarketanalytics.com/reports/769-global-dengue-vaccines-market

Customization Service of the Report:-
AMA Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, West Europe or Southeast Asia.

Contact US :
Craig Francis (PR & Marketing Manager)
AMA Research & Media LLP
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@advancemarketanalytics.com

Connect with us at
https://www.linkedin.com/company/advance-market-analytics
https://www.facebook.com/AMA-Research-Media-LLP-344722399585916
https://twitter.com/amareport

About Author:
Advance Market Analytics is Global leaders of Market Research Industry provides the quantified B2B research to Fortune 500 companies on high growth emerging opportunities which will impact more than 80% of worldwide companies' revenues.
Our Analyst is tracking high growth study with detailed statistical and in-depth analysis of market trends & dynamics that provide a complete overview of the industry. We follow an extensive research methodology coupled with critical insights related industry factors and market forces to generate the best value for our clients. We Provides reliable primary and secondary data sources, our analysts and consultants derive informative and usable data suited for our clients business needs. The research study enable clients to meet varied market objectives a from global footprint expansion to supply chain optimization and from competitor profiling to M&As.

This release was published on openPR.